Details

Autor(en) / Beteiligte

• Emmenegger, Marc
• De Cecco, Elena
• Lamparter, David
• Jacquat, Raphaël P.B.
• Riou, Julien
• Menges, Dominik
• Ballouz, Tala
• Ebner, Daniel
• Schneider, Matthias M.
• Morales, Itzel Condado
• Doğançay, Berre
• Guo, Jingjing
• Wiedmer, Anne
• Domange, Julie
• Imeri, Marigona
• Moos, Rita
• Zografou, Chryssa
• Batkitar, Leyla
• Madrigal, Lidia
• Schneider, Dezirae
• Trevisan, Chiara
• Gonzalez-Guerra, Andres
• Carrella, Alessandra
• Dubach, Irina L.
• Xu, Catherine K.
• Meisl, Georg
• Kosmoliaptsis, Vasilis
• Malinauskas, Tomas
• Burgess-Brown, Nicola
• Owens, Ray
• Hatch, Stephanie
• Mongkolsapaya, Juthathip
• Screaton, Gavin R.
• Schubert, Katharina
• Huck, John D.
• Liu, Feimei
• Pojer, Florence
• Lau, Kelvin
• Hacker, David
• Probst-Müller, Elsbeth
• Cervia, Carlo
• Nilsson, Jakob
• Boyman, Onur
• Saleh, Lanja
• Spanaus, Katharina
• von Eckardstein, Arnold
• Schaer, Dominik J.
• Ban, Nenad
• Tsai, Ching-Ju
• Marino, Jacopo
• Schertler, Gebhard F.X.
• Ebert, Nadine
• Thiel, Volker
• Gottschalk, Jochen
• Frey, Beat M.
• Reimann, Regina R.
• Hornemann, Simone
• Ring, Aaron M.
• Knowles, Tuomas P.J.
• Puhan, Milo A.
• Althaus, Christian L.
• Xenarios, Ioannis
• Stuart, David I.
• Aguzzi, Adriano

Titel

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Ist Teil von

• iScience, 2023-02, Vol.26 (2), p.105928-105928, Article 105928

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72′250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae. [Display omitted] •We continuously assessed SARS-CoV-2 seroprevalence in two cohorts (n = 72′250).•Modeled cumulative incidence was 3 × higher than suggested by PCR-based testing•On the population level, antibody half-life was 75 days•10% of individuals maintained symptoms one year post–COVID-19 Immunology; Microbiology; Virology; Biological database